Pharmaceutical Composition

Abstract

The present invention relates to the field of pharmacy, particularly to a pharmaceutical composition for oral administration comprising an (a) inert substrate and a (b) mixture comprising a non-bile acid farnesoid X receptor (FXR) agonist, such as 2-[(1R,3r,5S)-3-({5-cyclopropyl-3-[2-(trifluoromethoxy)phenyl]-1,2-oxazol-4-yl}methoxy)-8-azabicyclo[3.2.1]octan-8-yl]-4-fluoro-1,3-benzothiazole-6-carboxylic acid, or a pharmaceutically acceptable salt thereof, and at least one binder. The present invention also relates to a process for preparing said pharmaceutical composition for oral administration; and to the use of said pharmaceutical composition in the manufacture of a medicament.

1 . A pharmaceutical composition for oral administration comprising (a) an inert substrate, and (b) a mixture comprising 2-[(1R,3r,5S)-3-({5-cyclopropyl-3-[2-(trifluoromethoxy)phenyl]-1,2-oxazol-4-yl}methoxy)-8-azabicyclo[3.2.1]octan-8-yl]-4-fluoro-1,3-benzothiazole-6-carboxylic acid, or a pharmaceutically acceptable salt thereof, and at least one binder. 
     
     
         2 . The pharmaceutical composition of  claim 1 , wherein 2-[(1R,3r,5S)-3-({5-cyclopropyl-3-[2-(trifluoromethoxy)phenyl]-1,2-oxazol-4-yl}methoxy)-8-azabicyclo[3.2.1]octan-8-yl]-4-fluoro-1,3-benzothiazole-6-carboxylic acid is in a free form. 
     
     
         3 . The pharmaceutical composition of  claim 1 , wherein the (a) inert substrate comprises a material selected from the group consisting of lactose, microcrystalline cellulose, mannitol, sucrose, starch, granulated hydrophilic fumed silica, or mixtures thereof. 
     
     
         4 . The pharmaceutical composition of  claim 1 , wherein the binder is selected from the group consisting of polyvinyl pyrrolidone, hydroxypropyl cellulose, hypromellose, carboxymethyl cellulose, methyl cellulose, hydroxyethyl cellulose, carboxyethyl cellulose, carboxymethylhydroxyethyl cellulose, polyethylene glycol, polyvinylalcohol, shellac, polyvinyl alcohol-polyethylene glycol co-polymer, or a mixtures thereof. 
     
     
         5 . The pharmaceutical composition of  claim 1 , wherein the pharmaceutical composition is a particle. 
     
     
         6 . The pharmaceutical composition according to  claim 5 , wherein the particle further comprises an outer (c) seal coating layer. 
     
     
         7 . The pharmaceutical composition according to  claim 6 , wherein the outer (c) seal coating layer is selected from the group consisting of hydroxypropyl methyl cellulose, polyvinyl pyrrolidone, hydroxypropyl cellulose, carboxymethyl cellulose, methyl cellulose, hydroxyethyl cellulose, carboxyethyl cellulose, carboxymethylhydroxyethyl cellulose, polyethylene glycol, polyvinylalcohol, or mixtures thereof. 
     
     
         8 . The pharmaceutical composition according to  claim 1 , comprising at least one further active pharmaceutical ingredient. 
     
     
         9 . A final dosage form comprising the pharmaceutical composition according to  claim 1 , wherein the final dosage form is a capsule, a tablet, a mini-tablet, a sachet, or a stickpack. 
     
     
         10 . The final dosage form according to  claim 9 , wherein the final dosage form is a capsule or a tablet. 
     
     
         11 . The final dosage form according to  claim 9 , comprising 2-[(1R,3r,5S)-3-({5-cyclopropyl-3-[2-(trifluoromethoxy)phenyl]-1,2-oxazol-4-yl}methoxy)-8-azabicyclo[3.2.1]octan-8-yl]-4-fluoro-1,3-benzothiazole-6-carboxylic acid, or a pharmaceutically acceptable salt thereof, in an amount of about 0.01 mg to about 2 mg. 
     
     
         12 . A process for preparing a pharmaceutical composition for oral administration comprising (a) an inert substrate, and (b) a mixture comprising 2-[(1R,3r,5S)-3-({5-cyclopropyl-3-[2-(trifluoromethoxy)phenyl]-1,2-oxazol-4-yl}methoxy)-8-azabicyclo[3.2.1]octan-8-yl]-4-fluoro-1,3-benzothiazole-6-carboxylic acid, or a pharmaceutically acceptable salt thereof, and at least one binder,
 the process comprising the steps of:   (i) mixing the 2-[(1R,3r,5S)-3-({5-cyclopropyl-3-[2-(trifluoromethoxy)phenyl]-1,2-oxazol-4-yl}methoxy)-8-azabicyclo[3.2.1]octan-8-yl]-4-fluoro-1,3-benzothiazole-6-carboxylic acid, or a pharmaceutically acceptable salt thereof, with the at least one binder to form the mixture; and   (ii) adding the mixture of step (i) to the inert substrate.   
     
     
         13 . The process of  claim 12 , wherein step (i) comprises mixing further with at least one protic polar solvent, wherein the process further comprising the step of:
 (iii) removing the at least one protic polar solvent.   
     
     
         14 . The process of  claim 13 , wherein the at least one protic polar solvent is selected from the group consisting of organic solvents, water, or mixtures thereof. 
     
     
         15 . The process of  claim 14 , wherein the organic solvent is selected from the group consisting of methanol, ethanol, isopropanol, n-propanol, n-butanol, or mixtures thereof. 
     
     
         16 . The process of  claim 12 , wherein in step (ii) adding the mixture of step (i) to the inert substrate comprises dispersing the mixture of step (i) onto the (a) inert substrate. 
     
     
         17 . The process of  claim 12 , wherein in step (ii) adding the mixture of step (i) to the inert substrate comprises coating the (a) inert substrate with the mixture of step (i). 
     
     
         18 . The process of  claim 12 , wherein the pharmaceutical composition is a particle, and wherein the process further comprises the step of adding an outer (c) seal coating layer onto said particle. 
     
     
         19 . The process according to  claim 12 , further comprising the step of adding at least one additional active pharmaceutical ingredient. 
     
     
         20 . A method of treating a disease or disorder in a patient in need thereof, wherein the disease or disorder is cholestasis, intrahepatic cholestatis, estrogen-induced cholestasis, drug-induced cholestasis, cholestasis of pregnancy, parenteral nutrition-associated cholestasis, primary biliary cirrhosis (PBC), non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), liver cirrhosis, alcohol-induced cirrhosis, cystic fibrosis, or liver fibrosis, comprising the step of administering to the patient an effective amount of the pharmaceutical composition of  claim 1 .